Physician

Gregoire Bergier, MD

According to 2025 Medicare claims, Gregoire Bergier, MD (NPI: 1528098720) practices hematology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33761-2029.

Bergier's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 642 traditional Medicare patients, billed 178,104 HCPCS/CPT codes, and received $2,500,109 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,487 prescription claims across 255 beneficiaries totaling $4,538,654 in drug costs, led by Revlimid (Lenalidomide). DME data shows 62 claims. Open Payments data shows 101 records totaling $2,275. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $2,076,602 to $4,538,654. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	893	226,830	$2,610,483
2016	1,064	353,010	$3,739,540
2017	1,058	338,444	$3,849,005
2018	1,031	341,366	$4,426,433
2019	1,048	346,468	$3,791,846
2020	692	250,067	$3,389,365
2021	601	242,776	$3,022,178
2022	595	209,772	$2,463,119
2023	844	203,086	$2,660,957
2024	642	178,104	$2,500,109

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	233	1,364	$2,076,602
2016	256	1,604	$2,855,669
2017	252	1,651	$2,820,319
2018	234	1,476	$2,751,019
2019	210	1,285	$2,843,565
2020	209	1,244	$2,662,437
2021	227	1,318	$2,443,921
2022	221	1,212	$2,668,194
2023	295	1,657	$4,121,390
2024	255	1,487	$4,538,654

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	190	$32,318
2016	N/R	205	$25,149
2017	N/R	104	$24,018
2018	N/R	25	$1,319
2019	N/R	55	$4,245
2020	N/R	29	$3,648
2021	N/R	N/R	N/R
2022	N/R	15	$1,447
2023	N/R	45	$6,248
2024	N/R	62	$2,856

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	283	770	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	285	617	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	159	264	$13
36415	Insertion of needle into vein for collection of blood sample	452	1,423	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	468	1,698	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	80	2,184	$1,275,213
Imbruvica	Ibrutinib	68	1,942	$911,320
Venclexta	Venetoclax	16	480	$262,756
Ibrance	Palbociclib	15	420	$236,466
Brukinsa	Zanubrutinib	14	420	$201,777

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	11	$1,777
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$558
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$276
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	101	$2,275	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gregoire Bergier, MD?

Tedicare shows public-source Medicare data for Gregoire Bergier, MD (NPI 1528098720), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gregoire Bergier, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Gregoire Bergier, MD?

Gregoire Bergier, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Gregoire Bergier, MD have Open Payments data?

Gregoire Bergier, MD has 101 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.